Register now
To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.
Already have an account?
If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.
Over 52 weeks in patients > 12 years old with severe asthma with both treatment arms as an add-on to background asthma therapy,
TEZSPIRE® demonstrated statistically significant and clinically meaningful reductions in AAER requiring ER visits/hospitalization vs. placebo (secondary endpoint)1*
Fictitious patients. May not be representative of general population.
Key secondary endpoints for the NAVIGATOR study1
Change from baseline in:
In the NAVIGATOR trial, various factors such as treatment, geographical region, age group, and the participant’s history of exacerbations (flare-ups) were included as covariates for the rate of asthma exacerbations.
* The annual asthma exacerbations and exacerbations requiring emergency room visit/hospitalization were analyzed through a negative binomial regression model, with the logarithm of time at risk included as an offset variable. Rates are the total number of asthma exacerbations in each group/total person-year follow-up in each group with exact Poisson confidence intervals. In NAVIGATOR, estimated marginal rates are presented from the model. AAER, annualized asthma exacerbations rate; ACQ-6, Asthma Control Questionnaire 6; AQLQ(S)+12; Standardised Asthma Quality of Life Questionnaire for ages 12 and older;
CI, confidence interval; ER, emergency room; FEV1, forced expiratory volume in one second; RR, rate ratio
Reference:
Last reviewed: Sept 2024
TEZSPIRE® and the logo are trademarks of Amgen Inc. and the Amgen logo is a registered trademark of Amgen Inc., used under license by AstraZeneca Canada Inc.
© 2024 AstraZeneca Canada Inc. All rights reserved.
AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
TEZSPIRE® and the logo are trademarks of Amgen Inc. and the Amgen logo is a registered trademark of Amgen Inc., used under license by AstraZeneca Canada Inc.
© 2024 AstraZeneca Canada Inc. All rights reserved.
AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
La información contenida en este sitio web está dirigida exclusivamente a profesional sanitario facultado para prescribir o dispensar medicamentos en España (requiere una formación especializada para su correcta interpretación)AstraZeneca promueve la prescripción de sus productos farmacéuticos en las condiciones establecidas en su ficha técnica.
